Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Gemox in Advanced ICC
NCT04961788Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04961788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961788.